The efficacy of human epidermal growth factor receptor 2-targeted therapies, such as humanized monoclonal antibody trastuzumab (Herceptin®, Roche), in patients with breast-to-brain cancer metastasis is hindered by the low permeability of the blood-brain barrier (BBB).NeOnc conducted an in vitro and in vivo study to look at the ability of NEO100 to assist in delivering trastuzumab across the BBB in order to more effectively deliver the therapeutic to a tumor site.

The study showed that NEO100 increased trastuzumab penetration across both in vitro BBB delivery and in vivo intravenous delivery resulting in brain tumor-selective accumulation of trastuzumab, without a detectable presence in normal brain tissue, along with the increased presence of immune cell populations. As a result, it is suggested that NEO100 facilitates brain tumor entry of trastuzumab and T-DM1 and enhances its therapeutic efficacy, along with increased antibody-dependent immune cell recruitment.

Read The Paper

Enhanced Brain Delivery And Therapeutic Activity Of Trastuzumab After Blood-Brain Barrier Opening By NEO100 In Mouse Models Of Brain-Metastatic Breast Cancer.

Authors: Weijun Wang^{† 1}, Haiping He^†5, Nagore I. Marín-Ramos¹, Shan Zeng⁵, Steven D. Swenson¹, Hee-Yeon Cho¹, Jie Fu⁶, Paul M. Beringer⁴, Josh Neman³, Ligang Chen⁵, Axel H. Schönthal², Thomas C. Chen^1,3

¹Department of Neurological Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, ²Department of Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, ³Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA, ⁴Department of Clinical Pharmacy, University of Southern California, Los Angeles, California, USA, ⁵School of Pharmacy, University of Southern California, Los Angeles, California, USA., ⁶Department of Neurosurgery, Affiliated Hospital of Southwest Medical University, Luzhou, China